Amplia Therapeutics Ltd
ATX
Company Profile
Business description
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.
Contact
350 Queen Street
Level 17
MelbourneVIC3000
AUST: +61 280033650
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,524.30 | 323.30 | -4.12% |
| CAC 40 | 7,274.95 | 324.03 | -4.26% |
| DAX 40 | 20,641.72 | 1,075.67 | -4.95% |
| Dow JONES (US) | 38,445.03 | 2,100.90 | -5.18% |
| FTSE 100 | 8,049.07 | 5.91 | -0.07% |
| HKSE | 20,038.37 | 2,811.44 | -12.30% |
| NASDAQ | 15,587.79 | 962.82 | -5.82% |
| Nikkei 225 | 31,136.58 | 2,644.00 | -7.83% |
| NZX 50 Index | 11,775.88 | 449.40 | -3.68% |
| S&P 500 | 5,084.85 | 311.67 | -5.78% |
| S&P/ASX 200 | 7,343.30 | 324.50 | -4.23% |
| SSE Composite Index | 3,107.30 | 234.71 | -7.02% |